SecBot SecBot
SECBOTREPLAY Home › Report › TECH

TECH · Bio-Techne reported Q4 FY2026 adjusted EPS of $0.52, a 2.1% beat vs…

Bio-Techne Corporation · PRESS-RELEASE filed Aug 12, 2026 at 06:30 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Aug 12, 2026 at 06:30 ET

Bio-Techne reported Q4 FY2026 adjusted EPS of $0.52, a 2.1% beat vs $0.52 consensus, on revenue of $321.2M (1% reported growth, 3% organic). Full-year revenue was flat at $1.2B. The results are largely procedural given the pending $73/share acquisition by Merck KGaA, with the company no longer holding earnings calls. The modest adjusted EPS decline and flat revenue are secondary to the deal's trajectory and premium.

  • Q4 FY2026 revenue $321.2M, +1% reported / +3% organic vs prior year
  • Adjusted EPS $0.52 vs $0.53 a year ago, beating consensus of $0.52
  • GAAP EPS $0.35 vs $(0.11) a year ago, driven by prior-year impairment
  • Full-year FY2026 revenue flat at $1.2B; adjusted EPS $1.93 vs $1.92

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access